BCL2 and non-small cell lung carcinoma: In accordance with our data, a preferential elimination of CSCs after Bcl-2 family proteins-targeted strategies was recently demonstrated in other models such as leukemia stem cells [56, 57] and non-small cell lung cancer [58].